医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Maxinovel Pharmaceuticals Announces the Presentation of Its Orally Active PD-1/PD-L1 Inhibitors in 2018 AACR

2018年02月27日 AM12:10
このエントリーをはてなブックマークに追加


 

GUANGZHOU, China

Maxinovel Pharmaceuticals today announces that it will present preclinical results of its orally active PD-1/PD-L1 inhibitors as a single agent or combination with Epacadostat, Celebrex, Cisplatin and CTLA-4, respectively. The presentation will be held in 2018 AACR in Chicago, USA. The details are as follows:

Title: Novel small molecule inhibitors of PD-1/PD-L1 pathway demonstrated single agent and drug combo effectiveness in cancer immunotherapy

Session Category: Experimental and Molecular Therapeutics

Session Title: Novel and Canonical Targets

Session Date and Time: Tuesday April 17, 2018 8:00am-12:00pm

Location: McCormick Place South, Exhibit Hall A, Poster Section 35

Poster Board Number: 17

Permanent Abstract Number: 3851

About Maxinovel Pharmaceuticals, Inc:

Maxinovel Pharmaceuticals, Inc. is a biotech company focusing on the discovery and development of Immuno-oncology therapy and targeted therapy. It will use its orally active Immuno-oncology product platform to bring effective combo product of multi-components in a single oral pill to the patients worldwide. For more info: www.maxinovel.com

View source version on businesswire.com: http://www.businesswire.com/news/home/20180226005313/en/

CONTACT

Maxinovel Pharmaceuticals
Ms. Pingjing Zhang
pjzhang@maxinovel.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Seoul Viosys’ Violeds Modules Proven to Disinfect 99% of Airborne Viruses in a Recent Testing Result
  • Aurinia Announces Collaboration and Licensing Agreement with Otsuka Pharmaceutical Co., Ltd. for the Development and Commercialization of Voclosporin in Europe and Japan
  • Kaye推出适用于冷链运输市场的Kaye® Log -80℃ 疫苗温度记录器,以满足COVID-19疫苗储存和运输的要求
  • Kaye® (ケイ)は、COVID-19ワクチンの輸送・保管のニーズに応えるためにKaye® ログ -80ワクチン温度ロガーを、コールドチェーン市場向けに導入(発売)します。
  • DNP的新型非接触式透明屏幕可通过手的动作进行操作